Projects / Programmes source: ARIS

MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance

Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
3.01  Medical and Health Sciences  Basic medicine 
antimicrobial resistance, new antibacterial drugs, extremely drug resistant bacteria, multi-targeted antibiotics
Evaluation (rules)
source: COBISS
Data for the last 5 years (citations for the last 10 years) on December 3, 2023; A3 for period 2017-2021
Data for ARIS tenders ( 04.04.2019 – Programme tender, archive )
Database Linked records Citations Pure citations Average pure citations
WoS  232  4,865  4,107  17.7 
Scopus  234  5,316  4,512  19.28 
Researchers (9)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  57579  Ivan Džajić  Pharmacy  Researcher  2022 - 2023 
2.  52168  Tjaša Felicijan  Pharmacy  Researcher  2021 - 2023  24 
3.  53671  Špela Gubič  Pharmacy  Researcher  2021 - 2023  17 
4.  34385  PhD Jasna Lojk  Metabolic and hormonal disorders  Researcher  2021  68 
5.  19317  PhD Lucija Peterlin Mašič  Pharmacy  Head  2021 - 2023  401 
6.  28334  PhD Tihomir Tomašić  Pharmacy  Researcher  2021 - 2023  363 
7.  52375  PhD Žan Toplak  Pharmacy  Researcher  2021 - 2023  24 
8.  23420  PhD Jurij Trontelj  Pharmacy  Researcher  2021 - 2023  252 
9.  53670  Živa Zajec  Pharmacy  Researcher  2022 - 2023  14 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0787  University of Ljubljana, Faculty of Pharmacy  Ljubljana  1626973  17,150 
There is an urgent need for new therapies and new antibiotics to treat deadly infections caused by so-called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species), which are often resistant to available antibiotics. Antimicrobial resistance (AMR) is becoming an increasingly urgent public health threat in both clinical and community settings. One promising strategy to address this rapid evolution of resistance is the design of antimicrobial compounds equipotently inhibit two bacterial targets. The rationale for this approach is that the development of resistance to multitargeting antibiotics (MTA) would require the simultaneous occurrence of multiple specific mutations at both targets, which is extremely rare. In the MTAvsAMR (new MultiTargeting Antibiotics against AntiMicrobial Resistance) research project, we aim to develop a new structural class of MTA against two well-established molecular targets with innovative approaches to potent and safe multitargeting antibiotics with limited resistance. We will target the antibacterial activity of the new molecules against ESKAPE pathogens to address an unmet medical need, with a target product profile of methicillin-resistant (MRSA), vancomycin-intermediate (VISA) Staphylococcus aureus and Acinetobacter baumannii clinical isolates. To overcome the limitations of the current multitargeting antibiotics and to drive further development, we have established an interdisciplinary consortium to address fundamental questions related to the design of new antibacterial compounds with limited resistance, suitable PADMET properties, and lower susceptibility to efflux mechanisms. Excellent facilities combined with some of the latest technologies and expertise (DIvERGE, electrophysiology, channel mutagenesis and molecular dynamics simulations) will support MTA optimization. The MTAvsAMR project will evaluate compounds in original PADMET platform, which is unique for an academic setting and one of the key benefits of the research project. This multidisciplinary project has a strong interest in commercialization.
Views history